• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem resets 2023 guidance due to reduced sales visibility from new product disruption

August 3, 2023 By Sean Whooley

Tandem Diabetes Care updated logoTandem Diabetes Care (Nasdaq:TNDM) shares took a hit on second-quarter results that included amended full-year financial guidance.

Changes to the automated insulin delivery technology maker’s outlook reflect updates to its portfolio and reduced visibility on sales for the near future.

Shares of TNDM fell 15% to $27.19 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.8%.

Due to additions to its portfolios and expected disruption ahead, Tandem amended its guidance for 2023. At the end of the first quarter, the company projected GAAP revenues ranging between $885 million and $900 million.

It now expects non-GAAP sales to reach at least $785 million for the year ending Dec. 31, 2023.

“The upcoming addition of four new offerings to our portfolio sets a path for renewed momentum as we bring the benefits of Tandem technology to more people living with diabetes worldwide,” said Leigh Vosseller, Tandem EVP and CFO. “In the near term, we anticipate that our measured rate of market releases has the potential for disruption and reduced sales visibility. We are resetting our guidance to provide our minimum sales expectation for the remainder of the year, while focusing on driving the success of our new offerings and operational efficiencies across the business.”

The company also projects gross margin to reach approximately 51%, with adjusted EBITDA margin forecast to break even as a percent of sales. That includes a 3% impact from operating costs associated with the acquisitions of Capillary Biomedical and AMF Medical.

A look at the second-quarter results for Tandem Diabetes Care

The San Diego-based company posted losses of $35.8 million. That amounts to 55¢ per share on sales of $195.9 million for the three months ended June 30, 2023.

The company came up shy of Wall Street expectations as experts projected losses per share of 53¢ and sales of $197.4 million. Tandem recorded a more than $20 million bottom-line slide deeper into the red on a sales dip of 2.2%.

Despite the performance dips, Tandem increased its worldwide installed base by 16% compared to the second quarter of 2022. It now has approximately 437,000 in-warranty customers. Pump shipments declined, though, from 32,114 over the three-month period last year to 29,494 this year.

The company also launched its Tandem Source data management application and enrolled patients in a type 2 diabetes trial. Additionally, last month, the FDA cleared Tandem Mobi, the world’s smallest durable insulin delivery system.

“In the second quarter, we demonstrated exceptional progress with our new technology innovations, while driving operational improvements throughout our business and achieving sales expectations,” said John Sheridan, president and CEO. “We are navigating 2023 to position Tandem for future growth and long-term success by delivering on the most exciting portfolio in insulin therapy management while furthering our mission to offer choice and simplified solutions to improve the lives of people with diabetes.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS